. Tables: Table S1 . Yields of syntheses of triazole-modified dinucleotide cap analogues. GpppG is average from 5 repetitions as for practical reasons the experiment was performed independently for groups of no more than 8 analogues. Table S4 . The susceptibility of triazole-containing cap analogues to degradation by hDcpS under high enzyme concentration determined by an HPLC assay. Conditions: 10 µM analogue, 200 nM hDcpS, 50 mM Tris-HCl, 200 mM KCl, 0.5 mM EDTA, 1 mM DTT. Figures: Figure S1 . water, the products were eluted using different gradients of TEAB in deionized water: 0-0.7 M for nucleoside monophosphates, 0-1.0 M for nucleoside diphosphates or 0-1.2 M nucleoside triphosphates. Fractions containing the desired product were collected together after RP HPLC and spectrophotometric analysis (at 260 nm). Evaporation under reduced pressure with repeated additions of 96% ethanol, then 99.8% ethanol and, at the end, MeCN resulted in isolation of nucleotide analogues as triethylammonium (TEA) salts.
Azide-modified compound

Analogue
1.2.2
Analytical and preparative reverse-phase (RP) HPLC Both analytical and semi-preparative HPLC were performed on Agilent Technologies Series 1200 with UV-detection at 254 nm and fluorescence detection (Ex: 260 nm, Em: 370 nm). For chemical and enzymatic reactions, monitoring analytical HPLC was performed using Supelcosil LC-18-T column (4.6 x 250 mm, 5 μm, flow rate 1.3 mL/min) with one of three different linear gradients of methanol in 0.05 M ammonium acetate buffer (pH 5.9): program A -gradient 0-25% of methanol in 15 min, program B -gradient 0-50% of methanol in 15 min, program C -gradient 0-50% of methanol in 7.5 min and then isocratic elution (50% of methanol) until 15 min. For pH-dependent degradation studies and reactions monitoring of different steps of ARCA analogues synthesis analytical HPLC was performed using Grace VisionHT C18-HL column (4.6 x 250 mm, 5μm, flow rate 1.3 mL/min) with linear gradient 0-25% of methanol in 0.05 M ammonium acetate buffer (pH 5.9) in 15 min. Semi-preparative RP HPLC was performed using Discovery RP Amide C-16 HPLC column (25 cm x 21.2 mm, 5 μm, flow rate 5.0 mL/min) with linear gradients of acetonitrile in 0.05 M ammonium acetate buffer (pH 5.9). The products, after at least triple lyophilisation, were isolated as ammonium salts.
Yields and concentrations determination
The yields of mononucleotide analogues after ion-exchange purification and the concentrations of mono-and dinucleotide analogues solutions used for biophysical and biological experiments were determined on the basis of absorbance measurements performed at 260 nm in 0.1 M phosphate buffer pH 6.0 for 7-methylguanine mononucleotide analogues and in 0.1 M phosphate buffer pH 7.0 for dinucleotide analogues and guanine mononucleotide analogues. The quantities of obtained ion-exchange purified products were expressed as optical density miliunits (opt. mu = absorbance of the solution by volume in mL). 
NMR spectroscopy and mass spectrometry
The structure and purity of each final product were confirmed by high resolution mass spectrometry using negative or positive electrospray ionization (HRMS (-) ESI or HRMS (+) ESI) and 1 H NMR, 31 Gp γ p β p α G.
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Phosphoramidate cap analogues (6a-d, 7a-9b) hydrolyzed in D 2 O gradually. Although pure compounds (see HPLC profiles, Supporting Information 2) were dissolved in D 2 O just before measurements, the spectra indicated some level of hydrolysis. % of hydrolysis is provided along with compound characterization data, if higher than 5%.
Chemical synthesis
Synthesis of nucleotide imidazolide derivatives (19a-h):
2.1.1
Preparation of compounds for imidazole-activation
Preparation of triethylammonium (TEA) salts
The commercially available guanosine 5'-monophosphate (GMP) disodium salt and tetrasodium pyrophosphate were converted into triethylammonium forms by passing their aqueous solutions (ca. 1 g/20 mL) through Dowex 50 W x 8 cationite. The collected eluates were evaporated under reduced pressure with repeated additions of ethanol and acetonitrile to dryness yielding the nucleotide triethylammonium salt as a white solid and triethylammonium pyrophosphate as colorless oil.
Triethylammonium phosphate was prepared by slowly adding triethylamine to the low-concentrated solution of H 2 PO 4 in water until pH 7 was obtained which was followed by evaporation to afford oily, colorless residue.
Synthesis of guanosine 5'-diphosphate (GDP), guanosine 5'-triphosphate (GTP) and 2'-O-methylguanosine 5'-diphosphate (m 2'-O
GDP)
Triethylammonium phosphate (4 equiv.) or triethylammonium pyrophosphate (4 equiv.) was suspended in DMF (ca. 0.4 M) in the presence of ZnCl 2 (4 equiv.) and stirred for ̴ 5 min to obtain a solution. Then, GMP-Im (19a) or m 2'-O GMP-Im (19g) (1 equiv.) along with a second portion of ZnCl 2 (4 equiv.) was added and the mixture was stirred for 1-2 h at room temperature. The reaction was stopped by 10-fold dilution with water and addition of EDTA (8 equiv.) and NaHCO 3 (ca. 17.6 equiv.). The ion-exchange purification afforded triethylammonium salt of GDP (64%), GTP (79%) and m 2'-O GDP (95%).
N7-methylation of guanine nucleotides (GMP, GDP and GTP)
An appropriate analogue (GMP, GDP or GTP, TEA salt) was dissolved in dry DMSO to obtain ca. 0.1 M solution followed by addition of CH 3 I (8 equiv.). The mixture was stirred at room temperature for several hours until HPLC analysis indicated more than 90% conversion of the substrate and the presence of N 7 -methylated nucleotide as the major product. The reaction was stopped by 10-fold dilution with water and organic-soluble compounds were removed by 3-time washing with diethyl ether. The aqueous phase was then treated with a pinch of Na 2 S 2 O 5 to reduce the residual iodine and the pH of solution was set to 7 by addition of solid NaHCO 3 . The following ionexchange purification afforded triethylammonium salt of m 7 GMP (63%), m 7 GDP (68%) or m 7 GTP (58%).
2.1.2
Imidazole-activation
Synthesis of nucleotide imidazolides
Compounds 19a-h were prepared according to Mukaiyama and Hashimoto. 5 An appropriate nucleotide (1 eq., TEA salt), imidazole (10 equiv.), 2,2′-dithiodipyridine (3 equiv.) were mixed in DMF ( ̴ 2.5 mL/100 mg of nucleotide) before addition of triethylamine (3 equiv.) and triphenylphosphine (3 equiv.). The mixture was stirred for 6-8 h at room temperature. The addition of a solution of anhydrous NaClO 4 (4 equiv.) in dry acetone ( ̴ 8 volumes of DMF volume) resulted in precipitation of the product as sodium salt. The suspension was cooled at 4 o C and the precipitate was filtered off, washed repeatedly with cold, dry acetone and dried in vacuum over P 4 O 10 . Yields 90-100 %.
Synthesis of phosphoester and C-phosphonate analogues 2.2.1 Synthesis of O-(2-propynyl) phosphate ester triethylammonium salt (18d)
Compound 18d was synthetized according to Lee et al with minor modifications. 6 Phosphorous acid (2.0 g, 24.4 mmol) was dissolved in propargyl alcohol (42.2 mL, 732.0 mmol, 30 equiv) and then triethylamine was added (10.12 mL, 73.2 mmol, 3.0 equiv). After 5 minutes of stirring, iodine (12.3 g, 48.8 mmol, 2.0 equiv) was added in portions. Then reaction was stirred for 30 min and then the mixture of cyclohexylamine (14.0 mL, 122 mmol, 5 equiv) in acetone (633 mL) was added. The white precipitate was centrifuged, and after removing the supernatant, resuspended in acetone. Procedure was repeated three times, then the precipitate was dried over P 2 O 5 in vacuum overnight. Using ion exchange chromatography the cyclohexylammonium salt was converted into the triethylamine salt to afford a yellowish oil (6.00 g, 17.8 mmol, 73% 
Synthesis of phosphoester nucleotide analogues
General procedure A (GP A): Coupling of nucleotide imidazolides with phosphoester subunit (18d)
Compound 18d (3 equiv.) was stirred in DMF until complete dissolution (to ̴ 0.3 M concentration). Then, 19a or 19b (1 equiv.) along with ZnCl 2 (8 equiv.) was added and the mixture was stirred for 1-2 h at room temperature. The reaction was stopped by 10-fold dilution with water and addition of EDTA (8 equiv.) and NaHCO 3 (ca. 17.6 equiv.). The product was purified by ion-exchange chromatography on DEAE Sephadex A-25 and evaporated to dryness as described in General Information. Prior to NMR characterization the product was additionally purified by semi-preparative HPLC as described in General Information.
General procedure B (GP B): N
7
-methylation of guanine nucleotides using CH 3 I An appropriate nucleotide (TEA salt) was dissolved in dry DMSO to obtain ca. 0.1 M solution followed by addition of CH 3 I (8 equiv.). The mixture was stirred at room temperature for several hours until HPLC analysis indicated more than 90% conversion of the substrate and the presence of N 7 -methylated nucleotide as the major product. The reaction was stopped by 10-fold dilution with water and organic-soluble compounds were removed by 3-time washing with diethyl ether. The aqueous phase was then treated with a pinch of Na 2 S 2 O 5 to reduce the residual iodine and the pH of solution was set to 7 by addition of solid NaHCO 3. The product was purified by ionexchange chromatography on DEAE Sephadex A-25 and evaporated to dryness as described in General Information. Prior to NMR characterization the product was additionally purified by semi-preparative HPLC as described in General Information.
General procedure C (GP C): N
7
-methylation of guanine nucleotides using (CH 3 ) 2 SO 4 An appropriate nucleotide (TEA salt) was dissolved at ̴ 0.2 M concentration in ca. 0.5 mM aqueous CH 3 COOH (pH 4) to obtain ca. 0.2 M solution. Then, 5 portions of (CH 3 ) 2 SO 4 (2 equiv. each) were added every 10 min to the mixture under vigorous stirring and the pH was maintained at 4 by adding 10% KOH if necessary. The stirring was continued at room temperature for several hours until HPLC analysis indicated more than 90% conversion of the substrate and the presence of N 7 -methylated nucleotide as the major product. The reaction was stopped by 10-fold dilution with water and organic-soluble compounds were removed by 3-time washing with diethyl ether. The pH of aqueous phase was then set to 7 by addition of solid NaHCO 3. The product was purified by ion-exchange chromatography on DEAE Sephadex A-25 and evaporated to dryness as described in General Information. Prior to NMR characterization the product was additionally purified by semi-preparative HPLC as described in General Information. 2 Briefly, triethylammonium 3-butynyl C-phosphonate (18a), tributylammonium 3-trimethylsilyl-1-propargyl C-phosphonate (18b) or triethylammonium 2-ethynyl C-phosphonate (18c) (each 2.5 equiv.) was stirred in DMF (ca. 0.4 M) until complete dissolution. Then, 19a or 19b (1 equiv.) along with MgCl 2 (8 equiv.) were added and the mixture was stirred for 1-2 h at room temperature. The reaction was stopped by 10-fold dilution with water. The product was purified by ion-exchange chromatography on DEAE Sephadex A-25 and evaporated to dryness as described in General Information to afford products in a form of triethylammonium salts. Trimethylsililpropargylophosphonate nucleotide analogues were then deprotected by incubation in TBAF/THF (1 M) : ACN (1:3, v/v) mixture (1.1 equiv. of TBAF per nucleotide) at room temperature for 24 h. After removing the solvent under reduced pressure, the crude product was directly subjected to click reactions. Yields: 45-90%. -C-(2-propargyl) 7-methylguanosine diphosphate ammonium salt Obtained according to GP B starting from β-C-(2-propargyl) guanosine diphosphate triethylammonium salt (11a) (8310 mOD, 0.688 mmol), CH 3 I 0.343 mL, 5.503 mmol) and DMSO (7.0 mL). The ion-exchange purification afforded 4706 mOD (0.413 mmol, 60%) of 11c triethylammonium salt. Additional HPLC purification of a fraction of obtained product gave 11c as ammonium salt. stopped by 10-fold dilution with water. The product was purified by ion-exchange chromatography on DEAE Sephadex A-25 and evaporated to dryness as described in General Information to afford 6385 mOD (0.528 mmol, 93%) of 12e triethylammonium salt. Additional HPLC purification of a fraction of obtained product gave 12e as ammonium salt. 
Synthesis of phosphoramidate nucleotide analogues General procedure D (GP D): Coupling of nucleotide imidazolides with amine linker
Analogues 15a-d were synthesized analogously as described in Guranowski et al. for the reaction of diamine linkers with guanosine 5'-phosphorimidazolide. 7 An appropriate nucleotide imidazolide (19a-f) was dissolved in 0.1 M Tris-HCl buffer pH 8.0 (approx. 1 mL per 100 mg nucleotide) and propargylamine or 2-azidoethyloamine (8 equiv.) was added. The mixture was stirred at room temperature for 24 h. The reaction was diluted with ten volumes of water and extracted with diethyl ether. After setting pH to 7 with 5% HCl, the mixture was either subjected to ion-exchange chromatography purification as described in General Information to afford the desired product as triethylammonium salt or directly purified by semi-preparative HPLC to afford the desired product as ammonium salt. (15c) N-(2-propargyl) β-phosphoramidate 7-methylguanosine diphosphate ammonium salt Obtained according to GP D starting from 7-methyl guanosine 5'-diphosphate β-Pimidazolide disodium salt (19e) (200 mg, 3060 mOD, 0.268 mmol) , propargylamine (0.138 mL, 2.147 mmol) and 2.0 mL of Tris-HCl buffer. The ion-exchange purification afforded 2077 mOD (0.182 mmol, 68%) of 15c triethylammonium salt. Additional HPLC purification of a fraction of obtained product gave 15c as ammonium salt. (1H, ddd, J 5'-5'' = 11.7, J = 4.9, 2.9, H5''), 3.35 (2H, t, J CH2(N3)-CH2(NH) = 5.9, H CH2(N3) ), 3.0 (2H, dt, J CH2(N3)-CH2(NH) 
Synthesis of phosphothioester nucleotide analogues Synthesis of thiophosphate nucleotide analogues (20a-d)
Analogues containing thiophosphate moiety at the terminal position of the phosphate chain (20a-d) were synthesized as described previously. 8 To a suspension of appropriate nucleotide imidazolide derivative (1 equiv.) and thiophosphate triethylammonium salt in DMF anhydrous ZnCl 2 was added (8 equiv.). The resulting solution was stirred for 20 min at room temperature. The reaction was quenched by 10-fold dilution with water and addition of EDTA (8 eq.) and NaHCO 3 (ca. 17.6 equiv.). The ion-exchange purification afforded triethylammonium salt of GDPβS (20a), GTPγS (20b), m 7
GDPβS (20c) and m 7
GTPγS (20d). Yields: 80-95%.
General procedure E (GP E): S-alkylation of thiophosphate nucleotide analogues
An appropriate nucleotide (20a-d) was dissolved in DMSO to a concentration of ca. 0.1 M and propargyl bromide (1 equiv.) was added. The mixture was stirred at room temperature for approx. 15 min. Then the reaction was diluted with ten volumes of water and extracted with diethyl ether. After setting pH to 7 (if needed), the mixture was subjected to ion-exchange chromatography purification as described in General Information to afford the desired product as triethylammonium salt.
(14a) S-(2-propargyl) β-phosphothioester guanosine diphosphate diammonium salt Obtained according to GP E starting from guanosine 5'-(β-thiodiphosphate) triethylammonium salt (20a) (3383 mOD, 0.280 mmol), propargyl bromide (21 µL) and DMSO (2.8 mL). The ion-exchange purification afforded 1819 mOD (0.150 mmol, 54%) of 14a triethylammonium salt. Additional HPLC purification of a fraction of obtained product gave 14a as diammonium salt. 5 mL) . The ion-exchange purification afforded 1125 mOD (0.099 mmol, 66%) of 14c triethylammonium salt. Additional HPLC purification of a fraction of obtained product gave 14c as ammonium salt. (16b) 5'-azido-5'deoxy-7-methylguanosine 5'-azido-5'deoxyguanosine (16a) (350 mg, 1.14 mmol) was dissolved in DMF (4 mL) and CH 3 I (566 µl, 9.09 mmol) was added. The mixture was stirred at room temperature for 3h (until 95% conversion into the desired product as determined by HPLC). The excess CH 3 I was removed under reduced pressure and the solution was concentrated to 0.5 mL. The resutling DMSO solution of 16b at 2.3 M concentration was stored at -20 o C and used for click reactions without any further treatment. 
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CuSO 4 or sodium ascorbate solutions or solvents (DMF or H 2 O) were added upon precipitation or slow kinetics. Final concentrations of reagents are given in the detailed procedures below. When completed, the reaction was quenched by 5-fold dilution with water and addition of Na 2 EDTA (ten equivalents of added CuSO 4 ) followed by direct semi-preparative RP HPLC purification. mL of DMF/H 2 O (2:1, v/v) for 3.5 h. After quenching the reaction with Na 2 EDTA (223.5 mg, 0.60 mmol), the product was subjected to RP HPLC purification which afforded 1d as ammonium salt. The reference 5'-triphosphate RNA1 and 5' capped RNA1 were obtained analogously but with usage of 0.5 mM GTP and no cap analogue or compound 1b instead of 10b, respectively.
General procedure G (GP G): Synthesis of dinucleotide cap analogues containing triazole located between P-subunits
To the aqueous solution of γ-C-(3-butynyl) 5'-triphosphate RNA1 (10.5 pmol) and 16b (0.525 nmol) the aqueous solution of CuSO 4 •5H 2 O (1.05 nmol), THPTA (2.1 nmol) and sodium ascorbate (2.1 nmol) was added. Final concentrations in reaction mixture were as follows: γ-C-(3-butynyl) 5'-triphosphate RNA1 -2.89 µM, 16b -144.6 µM, CuSO 4 •5H 2 O -289.2 µM , THPTA -578.5 µM, and sodium ascorbate -578.5 µM. The mixture was incubated at 37 o C for 1.5 h, then quenched by adding equal amount of loading dye (5 M urea, 44% formamide, 20 mM EDTA, 0.03% bromophenol blue, 0.03% xylene cyanol) and directly analyzed by 15% PAGE.
Synthesis of transcripts for capping efficiency determination
Prior to in vitro transcription annealing of a template was performed. DNA1 and DNA2 (20 µM each) were incubated in the presence of 4 mM Tris-HCl pH 8.0, 15 mM NaCl and 0.1 mM EDTA at 95 o C for 2 min and then at room temperature for 30 min. After 10-fold dilution the mixture was directly used for in vitro transcription.
In vitro transcription was performed on pre-annealed DNA1 and DNA2 (0.5 µM) with SP6 RNA polymerase (New England BioLabs) (1 U/µl) in the presence of 1x RNA Pol Reaction Buffer (New England BioLabs), 5 mM DTT, RiboLock RNase Inhibitor (ThermoFisher Scientific) (2.0 U/µl), 0.5 mM UTP, 0.5 mM ATP, 0.5 mM CTP, 0.125 mM GTP and 1.25 mM of appropriate triazole-modified dinucleotide cap analogue and reference GpppG, m 7 GpppG and m 2 7,3'-O GpppG. 3 The reaction mixture was incubated at 40 o C for 1.5 h followed by addition of TURBO Dnase (Ambion) (0.1 U/µl) and incubation at 37 o C for another 30 min. The reaction was quenched by addition of 2 µl of 0.5 M EDTA pH 8.0 and purified with RNA Clean&Concentrator-5 kit (Zymo Research) to afford capped RNA2 strands.
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To reduce heterogeneity, each capped RNA2 (11.42 ng/µl, ca. 1 µM) was incubated in presence of 50 mM Tris-HCl pH 8.0, 50 mM MgCl 2 , RiboLock RNase Inhibitor (ThermoFisher Scientific) (2.0 U/µl) and DNA3 (1 µM) at 37 o C for 1 h to afford RNA3. 1 The reaction was stopped by freezing in liquid nitrogen and directly analyzed by 15% PAGE.
Relative bands intensity was determined using CLIQS v1.0 program. with NucleoSpin RNA Clean-up XS kit (Macherey-Nagel) to afford luciferase-coding RNA strands capped with appropriate cap analogue.
Translation studies 3.3.1 Synthesis of transcripts
Translation
For each capped luciferase-coding RNA four diluted solutions were prepared -3.0 ng/µl, 1.5 ng/µl, 0.75 ng/µl, 0.375 ng/µl. Translation studies were performed using Rabbit Reticulocyte Lysate System (Promega). 9 µl of a mixture containing Rabbit Reticulocyte Lysate Translation efficiency was determined using Luciferase Reporter System (Promega). The samples were defrosted just before the experiment. To every sample 50 µl of Luciferase Assay Reagent was added just before measurement of luminescence on Synergy H1 Microplate Reader (Bio Tek). The measurement were performed for every four samples independently due to low stability of luminescence signal. The results are presented as proportions between regression coefficients of linear relationships between capped luciferase-coding RNA concentration in translation reaction (300 pg/µl, 150 pg/µl, 75 pg/µl, 37.5 pg/µl) and corresponding luminescence signal. Non-hydrolyzed fraction of the substrate (Y) at each time point was calculated as follows: Y = .
Studies of susceptibility to degradation by hDcpS
•( + )+ , where S -absorbance of the substrate, P 1 , P 2 -absorbance of the hydrolysis product(s).
The analogue was considered as resistant to degradation by hDcpS if no products of hydrolysis were observed after 24 h of incubation in the presence of the enzyme and then subjected to analogous experiment but using different enzyme and analogue concentrations -200 nM and 10 µM, respectively. In this case, the reaction was stopped after 30, 120 and 240 min.
